Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4
Clinical cancer research, Vol. 26, no. 6, p. 1220-1228 (2020) Hong, D S, Concin, N, Vergote, I, de Bono, J S, Slomovitz, B M, Drew, Y, Arkenau, H-T, Machiels, J-P, Spicer, J F, Jones, R, Forster, M D, Cornez, N, Gennigens, C, Johnson, M L, Thistlethwaite, F C, Rangwala, R A, Ghatta, S, Windfeld, K, Harris, J R, Lassen, U N & Coleman, R L 2020, ' Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer ', Clinical Cancer Research, vol. 26, no. 6, pp. 1220-1228 . https://doi.org/10.1158/1078-0432.CCR-19-2962